Schrodinger Inc (SDGR)

$17.67

+0.34

(+1.96%)▲

Market is closed - opens 7 PM, 14 Oct 2024

Performance

  • $17.34
    $18.12
    $17.67
    downward going graph

    1.9%

    Downside

    Day's Volatility :4.33%

    Upside

    2.48%

    downward going graph
  • $16.67
    $38.00
    $17.67
    downward going graph

    5.66%

    Downside

    52 Weeks Volatility :56.13%

    Upside

    53.5%

    downward going graph

Returns

PeriodSchrodinger IncSector (Health Care)Index (Russel 2000)
3 Months
-21.12%
3.8%
0.0%
6 Months
-33.19%
10.8%
0.0%
1 Year
-25.6%
18.9%
0.0%
3 Years
-65.6%
22.8%
-20.8%

Highlights

Market Capitalization
1.3B
Book Value
$6.51
Earnings Per Share (EPS)
-2.79
Wall Street Target Price
31.91
Profit Margin
-100.42%
Operating Margin TTM
-111.4%
Return On Assets TTM
-16.83%
Return On Equity TTM
-37.13%
Revenue TTM
200.6M
Revenue Per Share TTM
2.78
Quarterly Revenue Growth YOY
34.5%
Gross Profit TTM
101.0M
EBITDA
-200.5M
Diluted Eps TTM
-2.79
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.43
EPS Estimate Next Year
-2.47
EPS Estimate Current Quarter
-0.85
EPS Estimate Next Quarter
-0.86

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Schrodinger Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
4
4
4
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 80.59%

Current $17.67
Target $31.91

Company Financials

FY18Y/Y Change
Revenue
66.6M
↑ 19.65%
Net Income
-28.4M
↑ 63.44%
Net Profit Margin
-42.66%
↓ 11.43%
FY19Y/Y Change
Revenue
85.5M
↑ 28.37%
Net Income
-25.7M
↓ 9.65%
Net Profit Margin
-30.02%
↑ 12.64%
FY20Y/Y Change
Revenue
108.1M
↑ 26.36%
Net Income
-26.6M
↑ 3.72%
Net Profit Margin
-24.64%
↑ 5.38%
FY21Y/Y Change
Revenue
137.9M
↑ 27.6%
Net Income
-101.2M
↑ 279.99%
Net Profit Margin
-73.38%
↓ 48.74%
FY22Y/Y Change
Revenue
181.0M
↑ 31.19%
Net Income
-149.2M
↑ 47.39%
Net Profit Margin
-82.45%
↓ 9.07%
FY23Y/Y Change
Revenue
216.7M
↑ 19.73%
Net Income
40.7M
↓ 127.29%
Net Profit Margin
18.79%
↑ 101.24%
Q1 FY23Q/Q Change
Revenue
64.8M
↑ 13.97%
Net Income
129.1M
↓ 574.63%
Net Profit Margin
199.34%
↑ 247.21%
Q2 FY23Q/Q Change
Revenue
35.2M
↓ 45.68%
Net Income
4.3M
↓ 96.69%
Net Profit Margin
12.16%
↓ 187.18%
Q3 FY23Q/Q Change
Revenue
42.6M
↑ 20.97%
Net Income
-62.0M
↓ 1549.84%
Net Profit Margin
-145.7%
↓ 157.86%
Q4 FY23Q/Q Change
Revenue
74.1M
↑ 74.13%
Net Income
-30.7M
↓ 50.55%
Net Profit Margin
-41.38%
↑ 104.32%
Q1 FY24Q/Q Change
Revenue
36.6M
↓ 50.63%
Net Income
-54.7M
↑ 78.43%
Net Profit Margin
-149.53%
↓ 108.15%
Q2 FY24Q/Q Change
Revenue
47.3M
↑ 29.33%
Net Income
-54.0M
↓ 1.24%
Net Profit Margin
-114.18%
↑ 35.35%
FY18Y/Y Change
Total Assets
120.7M
↑ 108.08%
Total Liabilities
192.3M
↑ 86.0%
FY19Y/Y Change
Total Assets
155.3M
↑ 28.61%
Total Liabilities
248.6M
↑ 29.28%
FY20Y/Y Change
Total Assets
746.3M
↑ 380.62%
Total Liabilities
122.2M
↓ 50.83%
FY21Y/Y Change
Total Assets
756.5M
↑ 1.37%
Total Liabilities
199.4M
↑ 63.12%
FY22Y/Y Change
Total Assets
688.6M
↓ 8.98%
Total Liabilities
240.7M
↑ 20.7%
FY23Y/Y Change
Total Assets
803.0M
↑ 16.61%
Total Liabilities
254.4M
↑ 5.7%
Q1 FY23Q/Q Change
Total Assets
838.8M
↑ 21.81%
Total Liabilities
248.5M
↑ 3.25%
Q2 FY23Q/Q Change
Total Assets
841.6M
↑ 0.33%
Total Liabilities
230.3M
↓ 7.31%
Q3 FY23Q/Q Change
Total Assets
794.1M
↓ 5.63%
Total Liabilities
230.6M
↑ 0.1%
Q4 FY23Q/Q Change
Total Assets
803.0M
↑ 1.11%
Total Liabilities
254.4M
↑ 10.34%
Q1 FY24Q/Q Change
Total Assets
737.8M
↓ 8.12%
Total Liabilities
224.1M
↓ 11.93%
Q2 FY24Q/Q Change
Total Assets
688.4M
↓ 6.69%
Total Liabilities
214.4M
↓ 4.31%
FY18Y/Y Change
Operating Cash Flow
-23.7M
↑ 54.9%
Investing Cash Flow
11.2M
↑ 446.32%
Financing Cash Flow
80.3M
↑ 7010.1%
FY19Y/Y Change
Operating Cash Flow
-26.1M
↑ 9.9%
Investing Cash Flow
-53.9M
↓ 581.11%
Financing Cash Flow
28.7M
↓ 64.27%
FY20Y/Y Change
Operating Cash Flow
16.8M
↓ 164.3%
Investing Cash Flow
-381.7M
↑ 608.79%
Financing Cash Flow
541.3M
↑ 1787.02%
FY21Y/Y Change
Operating Cash Flow
-70.7M
↓ 521.73%
Investing Cash Flow
-16.8M
↓ 95.6%
Financing Cash Flow
8.0M
↓ 98.53%
FY22Y/Y Change
Operating Cash Flow
-119.7M
↑ 69.36%
Investing Cash Flow
90.0M
↓ 635.47%
Financing Cash Flow
2.1M
↓ 73.47%
Q1 FY23Q/Q Change
Operating Cash Flow
-31.1M
↑ 24.67%
Investing Cash Flow
172.2M
↑ 1390.02%
Financing Cash Flow
867.0K
↑ 79.88%
Q2 FY23Q/Q Change
Operating Cash Flow
-18.4M
↓ 40.69%
Investing Cash Flow
67.2M
↓ 60.95%
Financing Cash Flow
4.5M
↑ 421.8%

Technicals Summary

Sell

Neutral

Buy

Schrodinger Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Schrodinger Inc
Schrodinger Inc
-15.83%
-33.19%
-25.6%
-65.6%
-38.3%
Solventum Corp
Solventum Corp
-0.8%
8.53%
-1.45%
-1.45%
-1.45%
Doximity, Inc.
Doximity, Inc.
13.42%
67.57%
100.05%
-42.39%
-18.21%
Veeva Systems Inc.
Veeva Systems Inc.
-3.92%
2.22%
-2.15%
-26.11%
37.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
3.19%
5.51%
36.87%
50.49%
49.2%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Schrodinger Inc
Schrodinger Inc
43.22
NA
NA
-2.43
-0.37
-0.17
NA
6.51
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Doximity, Inc.
Doximity, Inc.
55.0
54.14
2.42
0.9
0.17
0.11
NA
4.92
Veeva Systems Inc.
Veeva Systems Inc.
56.5
56.5
1.21
4.76
0.13
0.06
NA
32.04
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
26.23
26.08
2.37
4.25
0.21
0.06
0.0
17.08
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Schrodinger Inc
Schrodinger Inc
Buy
$1.3B
-38.3%
43.22
-100.42%
Solventum Corp
Solventum Corp
Hold
$10.8B
-1.45%
NA
15.73%
Doximity, Inc.
Doximity, Inc.
Hold
$8.2B
-18.21%
55.0
32.53%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$34.2B
37.91%
56.5
23.91%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$41.5B
49.2%
26.23
8.1%

Insights on Schrodinger Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 36.59M → 47.33M (in $), with an average increase of 22.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -54.72M → -54.04M (in $), with an average increase of 1.3% per quarter

  • Vs DOCS

    In the last 1 year, Doximity, Inc. has given 99.9% return, outperforming this stock by 125.5%

  • Vs VEEV

    In the last 3 years, Schrodinger Inc has experienced a drawdown of -65.6%, however Veeva Systems Inc. resisted the overall trend and outperformed by 23.2%

Institutional Holdings

  • BlackRock Inc

    11.70%

  • Gates Bill & Melinda Foundation

    9.59%

  • Vanguard Group Inc

    9.40%

  • Rubric Capital Management LP

    4.30%

  • ARK Investment Management LLC

    3.36%

  • UBS Asset Mgmt Americas Inc

    2.97%

Company Information

schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. the predictive power of schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries that might otherwise not be possible. schrödinger also establishes deep partnerships and collaborations with companies in such fields as biotechnology, pharmaceuticals, chemicals, and electronics, and helped found the biotech company nimbus therapeutics. through significant long-term investments in basic research, schrödinger has made scientific breakthroughs across many areas of drug discovery and materials science. hundreds of peer-reviewed scientific publications by schrödinger scientists are frequently among the most heavily cited in their fields. founded in 1990, schrödinger has operations in the us, europe, japan, and india, with business part

Organization
Schrodinger Inc
Employees
867
CEO
Dr. Ramy Farid Ph.D.
Industry
Technology Services

Discover More

FAQs